CR20220541A - Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos - Google Patents

Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos

Info

Publication number
CR20220541A
CR20220541A CR20220541A CR20220541A CR20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A CR 20220541 A CR20220541 A CR 20220541A
Authority
CR
Costa Rica
Prior art keywords
binding
antigen
dll3
binding molecules
multispecific antigen
Prior art date
Application number
CR20220541A
Other languages
English (en)
Inventor
Shu Wen Samantha Ho
Tomoyuki Igawa
Sotaro Naoi
Shu Feng
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR20220541A publication Critical patent/CR20220541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación proporciona moléculas de unión a antígenos multiespecíficas que comprenden una primera fracción de unión a antígenos y una segunda fracción de unión a antígenos, cada una de las cuales es capaz de unirse a CD3 y CD137, pero no se une a CD3 y CD137 al mismo tiempo; y una tercera fracción de unión a antígenos que es capaz de unirse a DLL3, preferiblemente DLL3 humana, que inducen la citotoxidad dependiente de células T de manera más eficiente al tiempo que evitan los problemas de toxicidad adversa o los efectos secundarios que pueden tener otras moléculas multiespecíficas de unión a antígenos. La presente invención proporciona moléculas multiespecíficas de unión a antígenos y composiciones farmacéuticas que pueden tratar diversos tipos de cáncer, especialmente los asociados con DLL3, al comprender la molécula de unión al antígeno como ingrediente activo.
CR20220541A 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos CR20220541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062326 2020-03-31
PCT/JP2021/013460 WO2021200898A1 (en) 2020-03-31 2021-03-30 Dll3-targeting multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CR20220541A true CR20220541A (es) 2022-11-28

Family

ID=77855554

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220541A CR20220541A (es) 2020-03-31 2021-03-30 Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos

Country Status (18)

Country Link
US (3) US11274151B2 (es)
EP (1) EP4126969A4 (es)
JP (2) JP7085666B2 (es)
KR (2) KR20230035138A (es)
CN (1) CN115397866A (es)
AR (1) AR121695A1 (es)
AU (1) AU2021250186A1 (es)
BR (1) BR112022019498A2 (es)
CA (1) CA3173587A1 (es)
CL (1) CL2022002624A1 (es)
CO (1) CO2022015305A2 (es)
CR (1) CR20220541A (es)
IL (1) IL296803A (es)
MX (1) MX2022012091A (es)
PE (1) PE20230077A1 (es)
SG (1) SG11202105302PA (es)
TW (2) TW202325741A (es)
WO (1) WO2021200898A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
US11952422B2 (en) * 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3732195A4 (en) * 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
US20230121511A1 (en) * 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
JP7085666B2 (ja) 2020-03-31 2022-06-16 中外製薬株式会社 Ｄｌｌ３標的多重特異性抗原結合分子およびその使用
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0328966Y2 (es) 1987-10-16 1991-06-20
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
JP2002540763A (ja) 1999-02-10 2002-12-03 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３３個のヒト分泌タンパク質
WO2001012664A2 (en) 1999-08-19 2001-02-22 Chiron Corporation Notch receptor ligands and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1309614A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Novel secreted proteins and their uses
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
WO2004030615A2 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE602005027309D1 (de) 2004-01-16 2011-05-19 Regeneron Pharma Zur aktivierung von rezeptoren fähige fusionspolypeptide
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
SI1797127T1 (sl) 2004-09-24 2017-09-29 Amgen Inc. Modificirane fc-molekule
EA012162B1 (ru) 2004-10-22 2009-08-28 Эмджен Инк. Способ рефолдинга рекомбинантных антител
CN101123983A (zh) 2004-10-27 2008-02-13 米迪缪尼股份有限公司 特定修饰对相关抗原的亲和力来调节抗体的特异性
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
PL1772465T3 (pl) 2005-01-05 2009-08-31 F Star Biotechnologische Forschungs Und Entw M B H Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
CA2596248A1 (en) 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CN101336300A (zh) 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
CA2637267A1 (en) 2006-01-16 2007-07-19 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
WO2007121354A2 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
EP2522678A1 (en) 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
PT2155783E (pt) 2007-04-03 2013-11-07 Amgen Res Munich Gmbh Domínio de ligação específico inter-espécies
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
WO2009099961A2 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2260058A2 (en) 2008-04-07 2010-12-15 Ablynx N.V. Single variable domains against the notch pathways
EP2324061B1 (en) 2008-09-03 2017-04-12 F. Hoffmann-La Roche AG Multispecific antibodies
CN105601745B (zh) 2008-09-26 2020-09-08 Ucb医药有限公司 生物产品
ES2732191T3 (es) 2008-12-19 2019-11-21 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CN103328514B (zh) 2010-11-09 2015-12-02 阿尔蒂单抗治疗公司 用于抗原结合的蛋白复合物及其使用方法
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
PL3418306T3 (pl) 2011-10-11 2024-04-15 F. Hoffmann-La Roche Ag Ulepszone składanie przeciwciał dwuswoistych
US9868774B2 (en) 2011-10-20 2018-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
MX2014010074A (es) 2012-02-24 2014-09-12 Stem Centrx Inc Moduladores de ligando de tipo delta 3 (dll3) y metodos de uso.
TWI797443B (zh) 2012-05-30 2023-04-01 日商中外製藥股份有限公司 抗原結合分子之篩選或製造方法
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
SG11201606850QA (en) 2014-03-12 2016-09-29 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US20170274072A1 (en) 2014-03-26 2017-09-28 Tohoku University Bispecific antibody targeting human epidermal growth factor receptor
PL3130606T3 (pl) 2014-04-07 2022-02-07 Chugai Seiyaku Kabushiki Kaisha Przeciwciała dwuswoiste aktywujące układ odpornościowy
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
RU2017107502A (ru) 2014-09-12 2018-10-12 Дженентек, Инк. Антитела и конъюгаты, сконструированные введением цистеина
EP3219724A4 (en) 2014-11-11 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3305322A4 (en) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
KR20180030856A (ko) 2015-07-10 2018-03-26 메뤼스 엔.페. 인간 cd3 결합 항체
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
UA123323C2 (uk) 2016-05-02 2021-03-17 Ф. Хоффманн-Ля Рош Аг Димерний злитий поліпептид
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
BR112019007267A2 (pt) 2016-12-20 2019-07-09 Hoffmann La Roche anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3732195A4 (en) * 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
MX2020013348A (es) * 2018-06-09 2021-03-09 Boehringer Ingelheim Int Anticuerpos biespecificos contra dll3-cd3.
US20220195045A1 (en) 2018-08-03 2022-06-23 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
SG11202102882YA (en) 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule comprising altered antibody variable region
AU2019347412A1 (en) 2018-09-28 2021-05-27 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously
TW202028245A (zh) * 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
JP2023512390A (ja) 2020-02-05 2023-03-27 中外製薬株式会社 組換え抗原結合分子を製造するおよび／または濃縮するための方法
JP7085666B2 (ja) 2020-03-31 2022-06-16 中外製薬株式会社 Ｄｌｌ３標的多重特異性抗原結合分子およびその使用
US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules

Also Published As

Publication number Publication date
US11274151B2 (en) 2022-03-15
US20240010725A1 (en) 2024-01-11
EP4126969A4 (en) 2024-05-29
AU2021250186A1 (en) 2022-12-01
TWI799824B (zh) 2023-04-21
US11718672B2 (en) 2023-08-08
MX2022012091A (es) 2022-10-13
EP4126969A1 (en) 2023-02-08
IL296803A (en) 2022-11-01
TW202204409A (zh) 2022-02-01
US20210301016A1 (en) 2021-09-30
US20220251201A1 (en) 2022-08-11
KR102505383B1 (ko) 2023-03-02
JP7085666B2 (ja) 2022-06-16
JP2022122972A (ja) 2022-08-23
KR20230035138A (ko) 2023-03-10
CA3173587A1 (en) 2021-10-07
CN115397866A (zh) 2022-11-25
SG11202105302PA (en) 2021-11-29
WO2021200898A1 (en) 2021-10-07
CL2022002624A1 (es) 2023-06-02
AR121695A1 (es) 2022-06-29
BR112022019498A2 (pt) 2022-11-16
TW202325741A (zh) 2023-07-01
CO2022015305A2 (es) 2022-11-08
JP2021159081A (ja) 2021-10-11
KR20220100520A (ko) 2022-07-15
PE20230077A1 (es) 2023-01-11

Similar Documents

Publication Publication Date Title
CR20220541A (es) Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
EA202091135A1 (ru) Гидрофильные линкеры для конъюгатов антитело-лекарственное средство
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
ZA200709481B (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
WO2019152419A8 (en) Prc2 inhibitors
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
MX2022012092A (es) Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.
WO2020257278A3 (en) Small molecule target bromo/acetyl proteins and uses thereof
PH12021500011A1 (en) Anti-cd137 antigen-binding molecule and utilization thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
CR20220451A (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
AU2020264106A8 (en) Small molecule bromodomain inhibitors and uses thereof
WO2023240082A3 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
WO2022084355A3 (en) Agonistic trkb binding molecules for the treatment of eye diseases
MX2022007464A (es) Composiciones biofarmaceuticas y metodos relacionados.
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
WO2023034923A3 (en) BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF
MX2022014538A (es) Moleculas de union para el tratamiento de cancer.
WO2019018592A3 (en) PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide